Valneva SE (VALN) Net Cash Flow (2021 - 2026)
Valneva SE (VALN) posted Net Cash Flow of -$5.5 million for Q1 2026, up 86.87% sequentially from -$42.1 million in Q4 2025, and up 63.16% YoY from -$3.4 million in Q1 2025.
Analysis
Valneva SE (VALN) Net Cash Flow (2021 - 2026) Analysis & Trends
Valneva SE has reported Net Cash Flow for 6 years, with the latest figure at -$5.5 million in Q1 2026.
- Quarterly Net Cash Flow rose 63.16% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.6 million (down 107.07% YoY) and the FY2025 annual result came in at -$64.3 million, down 247.08% from the prior year.
- Net Cash Flow climbed to -$5.5 million in Q1 2026 per VALN's latest filing, from -$42.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $80.7 billion in Q3 2023 and troughed at -$80.8 billion in Q2 2023.
- A 5-year average of -$16.7 million and a median of -$15.0 million in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 101594.25% in 2023, down 304144.48% in 2023.
- Over 5 years, Net Cash Flow stood at $30.6 million in 2022, then tumbled by 262.38% to -$49.7 million in 2023, then soared by 117.34% to $8.6 million in 2024, then sank by 588.95% to -$42.1 million in 2025, then jumped by 86.87% to -$5.5 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$5.5 million, -$42.1 million, and -$19.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 18.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.73 Mn |
| Mar 31, 2026 | -5.53 Mn |
| Dec 31, 2025 | -39.58 Mn |
| Sep 30, 2025 | -19.06 Mn |
| Jun 30, 2025 | 13.09 Mn |
| Mar 31, 2025 | -15.02 Mn |
| Dec 31, 2024 | 10.27 Mn |
| Sep 30, 2024 | 29.05 Mn |
| Jun 30, 2024 | -48.55 Mn |
| Mar 31, 2024 | 55.35 Mn |
| Dec 31, 2023 | -48.38 Mn |
| Sep 30, 2023 | 87.94 Bn |
| Jun 30, 2023 | -88.06 Bn |
| Mar 31, 2023 | -33.56 Mn |
| Dec 31, 2022 | 30.77 Mn |
| Sep 30, 2022 | -79.54 Mn |
| Jun 30, 2022 | 26.25 Mn |
| Mar 31, 2022 | -39.28 Mn |
| Dec 31, 2021 | 111.05 Mn |
| Sep 30, 2021 | -96.18 Mn |